Bellicum reports first quarter 2021 financial results and provides operational update

Houston, may 17, 2021 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update.
BLCM Ratings Summary
BLCM Quant Ranking